Jackson Center, PA, Feb. 28, 2018 (GLOBE NEWSWIRE) — Premier Biomedical, Inc. (OTC: “BIEI“) announced today they are actively searching for a partner to develop their patented extracorporeal treatment process in combination with their patent pending method for treating diseases through the use of lasers. The methodology applies the concept of treating the blood outside the body in a continuous flow process, in combination with an emissive energy source, such as a laser, to destroy targeted antigens in the blood, prior to returning the blood to the patient. The company has exclusive rights to three issued patents, six pending applications and one provisional patent application, all related to innovative treatments for cancer and extracorporeal treatments for various life-threatening diseases.
Dr. Felder, inventor of the underlying technologies, stated, “The use of lasers in conjunction with our extracorporeal treatment process is an exciting concept, as it should completely eliminate any infectious disease, without the possibility of pathogen resistance, or the causation of side effects from the treatment. It also has the potential for being an inexpensive and efficacious treatment for septicemia — a leading cause of death worldwide.”
William A. Hartman, President & CEO of Premier Biomedical, indicated, “We believe this combination of our patented extracorporeal treatment process with our patent pending emissive energy ablation of targeted antigens could open a complete new chapter in the way diseases are treated. The safety and efficacy of treatment protocols for a wide range of diseases could be greatly improved.”
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
For more information please contact: William A. Hartman President and CEO Premier Biomedical Pain Relief Meds (724) 633-7033 email@example.com www.premierbiomedical.com/